Financial Performance

More in Financial Performance

• Akums announces unaudited consolidated financial results for Q1 FY25

  The company’s CDMO segment which accounts for 77 per cent of total revenue and 93 per cent of the Adj EBITDA, grew to Rs 7,820 million an increase of 5.6 per cent year-on-year (YoY). This was driven by strong growth in sales volume of 13.9 per cent. Segment EBITDA also saw margin expansion of 106 bps to 15.5 per cent, growing 13.4 per cent YoY to Rs 1,212 million on the back of steady improvement in capacity utilisation and better product mix.

  

• Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO

  The company expects its shares to trade on the Nasdaq Global Market under the ticker symbol 'ZBIO'. Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities are the underwriters.

  

• Aurobindo Pharma to commercialise China plant in third quarter of FY25: CFO

  ​The company's Rs 2,400 crore Pen-G plant in Andhra Pradesh, which was approved under Production-Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country, will have a production capacity of around 15,000 tonnes annually.

  

• Novo Nordisk Pharmatech unit to build $220 mln plant in Denmark

  ​Novo Nordisk's Pharmatech unit will build a 1.5 billion Danish crowns ($220.83 million) plant in Denmark to meet significantly higher demand for the production of medicines to fight chronic diseases, the company said on Friday.

  

• Revenue of domestic API firms to see 7-8 pc increase by 2029: Report

  "Given the subsequent remission in many of these headwinds, ICRA expects revenues of its sample set of companies to grow by 7-8 per cent in FY2025, post an estimated increase of 3-5 per cent in FY2024," Icra Vice President & Sector Head - Corporate Ratings Deepak Jotwani said.

  

• Supriya Lifescience reports 21.7 per cent Y-o-Y revenue increase in Q1 FY24

  EBITDA for Q1 FY25 stood at Rs 62.54 crore, with an EBITDA margin of 38.9 per cent, as opposed to an EBITDA of Rs 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7 per cent. This marks a growth of 40.6 per cent YoY. The profit after tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24. The PAT margin stood at 27.8 per cent in Q1 FY25, compared to 21.6 per cent in Q1 FY24.

  

• Natco Pharma Q1 profit up 59 pc at Rs 668 cr

  Revenue from operations rose to Rs 1,363 crore from Rs 1,140 crore in the year-ago period, Natco Pharma said in a regulatory filing.

  

• Aurobindo Pharma Q1 net profit jumps 61 pc at Rs 919 cr

  Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement.

  

• Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter

  ​However, Lilly CEO David Ricks cautioned that patients could still encounter delays when filling prescriptions. He told analysts on a conference call Thursday that while Lilly can fill orders as it receives them, that doesn't mean that pharmacies will have all 12 doses of Mounjaro and Zepbound available.

  

• Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand

  ​The Canonsburg, Pennsylvania-based company also raised the 2024 sales outlook for its new product range, including Breyna - a biosimilar to Astrazeneca's asthma drug Symbicort - to between $500 million and $600 million, up from its previous range of $450 million to $550 million.

  

• JB Pharma records 12 per cent revenue growth in Q1

  Operating earnings before interest depreciation and taxes (EBITDA) improved by 20 per cent to Rs 292 crore in Q1 FY25 as compared to Rs 243 crore in Q1 FY24. Profit after taxes registered strong growth of 25 per cent to Rs 177 crore in Q1 FY25 vs Rs 142 crores in Q1 FY24.